Market closedNon-fractional
Atea/AVIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Atea
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Ticker
AVIR
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Boston, United States
Employees
74
Website
ateapharma.com
Atea Metrics
BasicAdvanced
$274M
Market cap
-
P/E ratio
-$1.96
EPS
0.19
Beta
-
Dividend rate
Price and volume
Market cap
$274M
Beta
0.19
Financial strength
Current ratio
13.284
Quick ratio
13.139
Long term debt to equity
0.286
Total debt to equity
0.439
Management effectiveness
Return on assets (TTM)
-15.56%
Return on equity (TTM)
-29.16%
Valuation
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-2.846
Growth
Earnings per share change (TTM)
49.28%
3-year earnings per share growth
51.45%
What the Analysts think about Atea
Analyst Ratings
Majority rating from 3 analysts.
Atea Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$63M
61.38%
Profit margin
0.00%
NaN%
Atea Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.34
-$0.40
-$0.47
-$0.75
-
Expected
-$0.47
-$0.48
-$0.50
-$0.61
-$0.77
Surprise
-27.66%
-16.08%
-5.37%
23.63%
-
Atea News
AllArticlesVideos
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
GlobeNewsWire·1 month ago
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
GlobeNewsWire·1 month ago
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atea stock?
Atea (AVIR) has a market cap of $274M as of July 06, 2024.
What is the P/E ratio for Atea stock?
The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of July 06, 2024.
Does Atea stock pay dividends?
No, Atea (AVIR) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Atea dividend payment date?
Atea (AVIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Atea?
Atea (AVIR) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Atea stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.